GeneDx Holdings Corp.
GeneDx Holdings Corp. (Nasdaq: WGS) provides clinical genetic testing and genomic information services, specializing in exome and genome sequencing to help clinicians diagnose rare and other genetic disorders. Its ExomeDx and GenomeDx tests serve patients through healthcare providers, with payments coming from… From the company’s description.
Over the twelve months to Jun 30, 2026, GeneDx Holdings Corp. reported revenue of $454.43M, up 25.4% from a year earlier, and a net loss of $106.36M. Its operating margin was −20.3%, and operations used $48.71M in cash. In fiscal 2025, it reported revenue of $427.54M, up 40.0% from fiscal 2024, and a net loss of $21.02M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What GeneDx Holdings Corp. does
In the company’s own words
GeneDx Holdings Corp. (Nasdaq: WGS) provides clinical genetic testing and genomic information services, specializing in exome and genome sequencing to help clinicians diagnose rare and other genetic disorders. Its ExomeDx and GenomeDx tests serve patients through healthcare providers, with payments coming from third-party payors, patients, business-to-business clients and healthcare partners. The company also offers rapid and ultraRapid genome testing and uses its GeneDx Infinity dataset to support genomic interpretation and biopharma discovery. Its business centers on diagnostic testing; substantially all 2025 revenue came from diagnostic test reports. Founded in 2000, GeneDx pioneered exome sequencing for rare and ultra-rare disorders and acquired Fabric Genomics in 2025, adding a platform for genomic interpretation and international expansion. At year-end 2025, its team included nearly 1,300 people; its dataset drew on more than 2.5 million tests, including over 1 million exomes and genomes, and more than 8 million phenotypic datapoints.
Company details
- Sector
- Health Care
- Industry (SIC)
- Health Services
- Headquarters
- STAMFORD, CT
- Fiscal year end
- December
- CIK
- 1818331
- SIC
- 8000
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns GeneDx Holdings Corp. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · GeneDx Holdings Corp.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do GeneDx Holdings Corp. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of GeneDx Holdings Corp.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in GeneDx Holdings Corp.'s last four quarterly filings that the numbers alone won't show?”